Aktis Oncology (AKTS) said Tuesday it closed its upsized initial public offering, raising about $365.4 million.
The offering included 17.65 million shares at $18 per share and an additional 2.65 million shares from the underwriter's full exercise of its overallotment option, the company said.
The sale of additional shares is expected to close on Wednesday, Aktis Oncology said.
The company's common stock began trading on the Nasdaq Global Select Market on Jan. 9 under the ticker symbol "AKTS."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments